Modeling Human Gamma Delta T Cells as Antitumor Agents In Vivo
Abstract
The central objective of this project is to provide mechanistic data that will support the development of human Vgamma9Vdelta2 T cells as an anti-tumor cellular immunotherapy for lymphomas driven by Epstein-Barr virus (EBV) infection. During this research period we have concluded our efforts on Major Task 1 and made progress on Major Tasks 2, 3, and 4. The most significant findings were: i) the observation that our gamma delta T immunotherapy cells express the CD16 receptor and can therefore mediate antibody-dependent cell-mediated cytotoxicity (ADCC); ii) identification of a new live cell imaging methodology to perform screening and optimization experiments that will make our studies more efficient and reduce our animal usage; iii) preliminary experimental results demonstrating effector responses by the gamma delta T immunotherapy cells against EBV-infected B lymphocytes, that suggest that the EBV-infected B cells have upregulated their production of key endogenous ligands that allow for TCR-mediated recognition of target cells by gamma delta T cells without the need for added drugs.
Document Details
- Document Type
- Technical Report
- Publication Date
- Aug 01, 2019
- Accession Number
- AD1087539
Entities
People
- Jenny Gumperz
Organizations
- University of Wisconsin–Madison